Acta Med. 2022, 65: 89-98
https://doi.org/10.14712/18059694.2022.24
The Choroid after Half-Dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy
References
1. Am J Ophthalmol 1996 Jan; 121(1): 26–34.
< C, Flammer J. Choroidal capillary and venous congestion in central serous chorioretinopathy. https://doi.org/10.1016/S0002-9394(14)70531-8>
2. Katsanos A, Gorgoli K, Konidaris V, Empeslidis T. An overview of risk factors, diagnosis and treatment of central serous chorioretinopathy. In: Patrick Evans (Ed). Central serous chorioretinopathy (CSCR): risk factors, diagnosis and management. Chapter 1, p: 1–32. Nova Science Publishers Inc, NY, USA, 2017.
3. Am J Ophthalmol 2005 Jan; 139(1): 87–99.
< FC, de la Longrais RR, Ravera G, et al. The foveal photoreceptor layer and visual acuity loss in central serous chorioretinopathy. https://doi.org/10.1016/j.ajo.2004.08.037>
4. Ophthalmology 1996 Dec; 103(12): 2070–9; discussion 2079–80.
< RF, Campeas L, Haas A, et al. Central serous chorioretinopathy in younger and older adults. https://doi.org/10.1016/S0161-6420(96)30386-2>
5. Eye (Lond) 2019 Jan; 33(1): 14–33.
< CMG, Lee WK, Koizumi H, Dansingani K, Lai TYY, Freund KB. Pachychoroid disease. https://doi.org/10.1038/s41433-018-0158-4>
<PubMed>
6. Invest Ophthalmol Vis Sci 2015 Aug; 56(9): 5229–37.
< MM, Breukink MB, van Grinsven MJ, et al. OCT Angiography Compared to Fluorescein and Indocyanine Green Angiography in Chronic Central Serous Chorioretinopathy. https://doi.org/10.1167/iovs.15-17140>
7. Invest Ophthalmol Vis Sci 2014 Jun 3; 55(6): 38939. Erratum in: Invest Ophthalmol Vis Sci 2014 Aug; 55(8): 4811–2.
S, Sakamoto T, Yamashita T, et al. Choroidal structure in normal eyes and after photodynamic therapy determined by binarization of optical coherence tomographic images.
8. Br J Ophthalmol 2003 Dec; 87(12): 1453–8.
< WM, Lam DS, Lai TY, Tam BS, Liu DT, Chan CK. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. https://doi.org/10.1136/bjo.87.12.1453>
<PubMed>
9. Retina 2020 Dec; 40(12): 2373–8.
< I, Arcos-Villegas G, Sastre M, Ruiz-Medrano J, Arias-Barquet L, Duker JS, Ruiz-Moreno JM. Changes in choriocapillaris, sattler, and haller layer thicknesses in central serous chorioretinopathy after half-fluence photodynamic therapy. https://doi.org/10.1097/IAE.0000000000002764>
10. Photodiagnosis Photodyn Ther 2014 Dec; 11(4): 519–25.
< R, Liu L, Li C, Chen L. Evaluation of the effects of photodynamic therapy on chronic central serous chorioretinopathy based on the mean choroidal thickness and the lumen area of abnormal choroidal vessels. https://doi.org/10.1016/j.pdpdt.2014.07.005>
11. Am J Ophthalmol 2014 Apr; 157(4): 852-60.
< S, Souied EH, Cavallero E, Weber M, Querques G. Assessment of choroidal topographic changes by swept source optical coherence tomography after photodynamic therapy for central serous chorioretinopathy. https://doi.org/10.1016/j.ajo.2013.12.029>
12. Retina 2016 Sep; 36(9): 1652–7.
< YR, Kim JW, Kim SW, Lee K. Choroidal thickness in patients with central serous chorioretinopathy: Assessment of Haller and Sattler Layers. https://doi.org/10.1097/IAE.0000000000000998>
13. Br J Ophthalmol 2017 Apr; 101(4): 433–7.
< T, Koizumi H, Maruko I, et al. Structural analyses of choroid after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy. https://doi.org/10.1136/bjophthalmol-2016-308921>
14. Invest Ophthalmol Vis Sci 2017 Apr 1; 58(4): 2002–10.
< M, Rosa R, Musetti D, Musolino M, Saccheggiani M, Traverso CE. Choroidal Vascular Flow Area in Central Serous Chorioretinopathy Using Swept-Source Optical Coherence Tomography Angiography. https://doi.org/10.1167/iovs.17-21417>
15. Retina 2016 Nov; 36(11): 2051–8.
< SY, Wang Q, Wei WB, Jonas JB. Optical coherence tomographic angiography in central serous chorioretinopathy. https://doi.org/10.1097/IAE.0000000000001064>
16. Am J Ophthalmol 2004 Jun; 137(6): 1073–80.
< M, Boyer DS, Thomas EL, Taban M. Chronic central serous chorioretinopathy: photodynamic therapy. https://doi.org/10.1016/j.ajo.2004.01.043>
17. Retina 2013 Feb; 33(2): 309–15.
< RM, Ruiz-Moreno JM, Gomez-Ulla F, et al. Photodynamic therapy for chronic central serous chorioretinopathy: a 4-year follow-up study. https://doi.org/10.1097/IAE.0b013e3182670fbe>
18. Retina 2012 Feb; 32 Suppl 1: 288–98.
< LA, Slakter JS, Gross NE, et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. 2003. https://doi.org/10.1097/IAE.0b013e31823f99a9>
19. Clin Ophthalmol 2012; 6: 1639–44.
GD, Kotsolis AI, Koutsandrea C, Georgalas I, Papaconstantinou D, Ladas ID. Multiple spots of photodynamic therapy for the treatment of severe chronic central serous chorioretinopathy.
20. Am J Ophthalmol 2010 Feb; 149(2): 307–315.e2.
< M, Cardascia N, Longo A, et al. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial. https://doi.org/10.1016/j.ajo.2009.08.026>
21. PLoS One 2018 Aug 27; 13(8): e0202930.
< DJ, Park UC, Kim ET, Yu HG. Choroidal vascularity changes in idiopathic central serous chorioretinopathy after half-fluence photodynamic therapy. https://doi.org/10.1371/journal.pone.0202930>
<PubMed>
22. Ophthalmology 2013 Sep; 120(9): 1901–8.
< LA, Adhi M, Regatieri CV, et al. Analysis of choroidal morphologic features and vasculature in healthy eyes using spectral-domain optical coherence tomography. https://doi.org/10.1016/j.ophtha.2013.01.066>
<PubMed>
23. J Clin Med 2020 Feb 21; 9(2): 595.
< C, Pellegrini M, Bernabei F, et al. Choroidal Vascularity Index: An In-Depth Analysis of This Novel Optical Coherence Tomography Parameter. https://doi.org/10.3390/jcm9020595>
<PubMed>
24. Graefes Arch Clin Exp Ophthalmol 2002 Sep; 240(9): 748-57.
< U, Viestenz A, Naumann GO, Laqua H, Michels S, Schmidt-Erfurth U. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. https://doi.org/10.1007/s00417-002-0517-4>
25. Invest Ophthalmol Vis Sci 1999 Sep; 40(10): 2322–31.
D, Kramer M, Kenny AG, et al. Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment.
26. Arch Ophthalmol 2002 Jun; 120(6): 835–44.
U, Laqua H, Schlötzer-Schrehard U, Viestenz A, Naumann GO. Histopathological changes following photodynamic therapy in human eyes.
27. Retina 2011 Oct; 31(9): 1921–7.
< I, Iida T, Sugano Y, Furuta M, Sekiryu T. One-year choroidal thickness results after photodynamic therapy for central serous chorioretinopathy. https://doi.org/10.1097/IAE.0b013e31822bf6b1>
28. Retina 2015 Aug; 35(8): 1555–60.
< BL, Yu HG. Choroidal thickness after full-fluence and half-fluence photodynamic therapy in chronic central serous chorioretinopathy. https://doi.org/10.1097/IAE.0000000000000511>
29. Am J Ophthalmol 2015 Jul; 160(1): 72–84.e1.
< YK, Ryoo NK, Woo SJ, Park KH. Choroidal Thickness Changes After Photodynamic Therapy and Recurrence of Chronic Central Serous Chorioretinopathy. https://doi.org/10.1016/j.ajo.2015.04.011>
30. Photodiagnosis Photodyn Ther 2018 Mar; 21: 375–8.
< A, Yesilkaya C, Alkin Z. Early choriocapillaris changes after half-fluence photodynamic therapy in chronic central serous chorioretinopathy evaluated by optical coherence tomography angiography: Preliminary results. https://doi.org/10.1016/j.pdpdt.2018.01.015>
31. Graefes Arch Clin Exp Ophthalmol 2019 May; 257(5): 905–12.
< S, Özcan G, Yanık Ö, Batıoğlu F, Özmert E. Vascular and structural alterations of the choroid evaluated by optical coherence tomography angiography and optical coherence tomography after half-fluence photodynamic therapy in chronic central serous chorioretinopathy. https://doi.org/10.1007/s00417-018-04226-6>
32. Graefes Arch Clin Exp Ophthalmol 2019 Jul; 257(7): 1365–72.
< SY, Pan CT, Wang Q, Shi XH, Jonas JB, Wei WB. Optical coherent tomographic angiographic pattern of the deep choroidal layer and choriocapillaris after photodynamic therapy for central serous chorioretinopathy. https://doi.org/10.1007/s00417-019-04318-x>
33. Photodiagnosis Photodyn Ther 2020 Jun; 30: 101742.
< G, Montorio D, Comune C, et al. Study of vessel density by optical coherence tomography angiography in patients with central serous chorioretinopathy after low-fluence photodynamic therapy. https://doi.org/10.1016/j.pdpdt.2020.101742>
34. J Clin Med 2020 Aug 24; 9(9): 2734.
< C, Piccolino FC, Nassisi M, Eandi CM. Choroidal Structure after Half-Dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy. https://doi.org/10.3390/jcm9092734>
<PubMed>
35. J Ophthalmol 2015; 2015: 134783.
< E, Cohen SY, Miere A, et al. Optical Coherence Tomography Angiography in Central Serous Chorioretinopathy. https://doi.org/10.1155/2015/134783>
<PubMed>
36. Retina 2015 Nov; 35(11): 2196–203.
< MC, Lumbroso B, Rispoli M. In vivo characterization of retinal vascularization morphology using optical coherence tomography angiography. https://doi.org/10.1097/IAE.0000000000000635>
37. Int J Retina Vitreous 2016 Sep 15; 2: 22.
< CV, Novais EA, Branchini L, et al. Choroidal thickness in older patients with central serous chorioretinopathy. https://doi.org/10.1186/s40942-016-0046-7>
<PubMed>
38. Ophthalmic Surg Lasers Imaging Retina 2019 Feb 1; 50(2): e26–e32.
< R, Seen S, Vaishnavi S, et al. Choroidal Vascularity Index Using Swept-Source and Spectral-Domain Optical Coherence Tomography: A Comparative Study. https://doi.org/10.3928/23258160-20190129-15>
39. Graefes Arch Clin Exp Ophthalmol 2022 Jun; 260(6): 1823–35.
< EE, Stavrakas P, Kozobolis V, Katsanos A, Georgalas I, Stefaniotou M. Evaluation of the choriocapillaris after photodynamic therapy for chronic central serous chorioretinopathy. A review of optical coherence tomography angiography (OCT-A) studies. https://doi.org/10.1007/s00417-022-05563-3>